Monday, June 29, 2026

Investor sentiment (33 responses):

• High interest: 1
• Medium: 12
• Maybe (with condition): 3
• Low: 5
• No interest: 7

Investor engagement:

• Groups invited to apply: 6
• Investors who invited the company to apply: 6
• Investors who requested a 1:1 connection: 2

Summary: A single-use surgical drill with a 100%-effective automatic stop — FDA-cleared, revenue-generating across 110 hospitals — presented its $10M Series A. The room respected the product and its safety differentiation, with six groups inviting the company to apply; the dominant discussion was valuation, with investors converging toward a lower pre-money as the path to broader engagement.

Investor sentiment (31 responses):

• High interest: 1
• Medium: 1
• Low: 9
• No interest: 14

Investor engagement:

• Groups invited to apply: 0
• Investors who invited the company to apply: 0
• Investors who requested a 1:1 connection: 1

Summary: A cobalt-chromium trapezium-bone implant for thumb CMC osteoarthritis presented its $3.5M seed. The technology and the rising-prevalence thesis drew interest, but the reception was gated on reimbursement — a prospective lead is completing diligence on whether coverage applies broadly. Interest was largely contingent on that question resolving favorably.

Investor sentiment (24 responses):

• High interest: 1
• Medium: 2
• Maybe (with condition): 1
• Low: 4
• No interest: 11

Investor engagement:

• Groups invited to apply: 1
• Investors who invited the company to apply: 1
• Investors who requested a 1:1 connection: 3

Summary: An evidence-based neurodevelopmental therapy for preterm NICU infants — suck-activated maternal-voice exposure with validated RCT outcomes — presented its $2M round. The science earned strong regard, with an existing-investor champion advocating; the discussion centered on the reimbursement/economic case (NICU DRGs) and whether the niche is large enough for a venture return.